Thomas Hoffmann

GENEART AG provides integrated system solutions for DNA engineering focusing on gene synthesis, evolution and plasmid services. The company provides the technologies for pharmaceutical and biotechnology companies, chemical industry and universities for the development and production of new bio therapeutics, vaccines and improved industrial enzymes. Its service portfolio is comprised of 4 fields of business, which range from the production of synthetic genes and the generation of gene variants/gene libraries in combinatorial biology right through to the production of plasmid DNA. The company was founded by Ralf Wagner and Marcus Graf in 1999 and is headquartered in Regensburg, Germany.

CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany.

vasopharm GmbH operates as a pharmaceutical company. It discovers and develops novel therapeutics for the treatment of cerebro and cardiovascular diseases and their consequences. The firm focuses on therapeutics influencing the bioavailability of nitric oxide. The company was founded by Harald Schmidt and Ulrich Walter in July 1998 and is headquartered in Wuerzburg, Germany.

EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively.

Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany.

LBBW Venture Capital GmbH (LBBW-VC) is part of the private equity arm and a wholly-owned subsidiary of LBBW-Landesbank Baden-Württemberg, a government-controlled regional bank based in southwestern Germany. Significant minority shareholders in LBBW include regional financial institutions and local government entities. LBBW-VC was established in 2000 and is headquartered in Stuttgart. The firm specializes in venture capital investing.

Creathor Venture Management GmbH is an independent private equity firm specialized in technology venture capital investing. Creathor was foundedi n 2003 and is headquartered in Bad Homburg near Frankfurt in central Germany. The management invests their own capital, and manages venture capital funds on behalf of institutions.

Fixatti Holding AG engages in the acquisition, management, and disposal of participating interests in firms in the trade, services, and industrial sectors, particularly in the field of adhesive technologies. The company was founded on May 10, 2005 and is headquartered in Wallisellen, Switzerland.

COI Partners AG (COI Partners) is a private equity firm founded in 2000. The firm is headquartered in Zurich.

AMMA Venture GmbH provides engineering services. The private company is based in Ingelheim, Germany. The CEOs are Mathias Albert Boehringer, Ramón Antonio Payano Baez. The German company was founded in 2007.

Phorms Education SE develops school locations by sourcing the necessary start-up funding, recruiting teachers and improving infrastructure. Its network includes seven German-English bilingual nurseries, primary, and secondary schools as well as the Heidelberg International School. The company was founded by Bea Beste in 2005 and is headquartered in Berlin, Germany.

Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts.

Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA.

Cryotherapeutics SA develops and markets a cryotherapy system, with focus on highlighting the safety and efficacy of cryoneergy in the cardiovascular system. The firm specializes in the design of a proprietary system to be used in the treatment of coronary artery diseases that cause heart attacks. Its focus areas encompass technology research, system development, and early-stage product commercialization. The company was founded by Randell L. Werneth, John Yianni and Maurice Buchbinder on September 8, 2009 and is headquartered in Cologne, Germany.

STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain.

Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria.

Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.

K & K Group AG operates as a holding Swiss company. The private company is based in Zug, CH. and has subsidiaries in Switzerland, United Kingdom and Germany.

Chundsell Medicals AB develops and markets novel molecular diagnostics for the treatment of cancer. Its product measures the expression pattern of selected embryonic stem cell genes in prostate cancer core needle biopsies. The company was founded by Sunne Rosell and Chunde Li in 2007 and is headquartered in Solna, Sweden.

Luxendo GmbH manufactures and sells Single Plane Illumination Microscopes. The firm offers MuVi-SPIM technology which provides four simultaneous orthogonal views on large living specimens without the need for sample rotation. The company was founded by Lars Hufnageland is headquartered in Heidelberg, Germany.

eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.

Tranquini GmbH engages in the manufacture and distribution of natural ingredient beverages. The company was founded by Ahmed Elafifi in April 2015 and is headquartered in Vienna, Austria.

Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany.

Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert.

T3 Pharmaceuticals AG provides medicines and treatment for cancer patient. The company was founded in May 2015 by Simon J. Ittig, Christoph A. Kasper, Marlise Amstutz and Helmut H. Kessmann and is headquartered in Basel, Switzerland.

Chrimotha Immobilien GmbH is a company based in Ingelheim, Germany. The CEOs of the German company are Mathias Albert Boehringer, Christian Boehringer.

Chrimotha Immobilien GmbH & Co. KG provides real estate services. The private company is based in Ingelheim am Rhein, Germany. The CEOs are Mathias Albert Boehringer, Christian Boehringer. The German company was founded in 1995.

Rinri Therapeutics Ltd. operates as a biotechnology company developing a novel cell-based therapy to restore hearing. The company was founded in 2018 and is headquartered in Sheffield, the United Kingdom.

TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany.

Part of Arkema SA, SDP Holding NV is an investment holding Belgian company. The company is based in Nazareth, Belgium. SDP Holding was founded in 2018.

WMT AG is a German research company that specializes in developing cancer therapies. WMT was founded in 2020 by Yves Guillermet and Claus Kremoser, with Claus Kremoser serving as the CEO since 2020.

EUROIMMUN Medizinische Labordiagnostika AG is a holding company, which engages in the development and production of test systems and automation solutions for the laboratory diagnosis of autoimmune and infectious diseases, allergies, and gene analyses. The company was founded by Winfried Stöcker in September 1987 and is headquartered in Luebeck, Germany.

Part of BCG Holding Group SCS, Boston Consulting Group Service GmbH is a German company that provides management consulting services. The company is based in Munich, Germany.